What is the recommended famciclovir (Famvir) dosing for recurrent herpes simplex virus infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Famciclovir Dosing for Recurrent HSV

For recurrent genital herpes in immunocompetent adults, famciclovir (Famvir) should be dosed at 1000 mg twice daily for 1 day for episodic treatment, or 250 mg twice daily for chronic suppressive therapy. 1

Episodic Treatment of Recurrent Episodes

The FDA-approved dosing for acute recurrent genital herpes is 1000 mg twice daily for 1 day 1. This single-day regimen should be initiated at the first sign or symptom of recurrence (tingling, itching, burning, pain, or lesion appearance). Treatment initiated more than 6 hours after symptom onset has not been adequately studied 1.

Alternative episodic dosing from CDC guidelines includes 125 mg twice daily for 5 days 2. While the 1-day regimen offers superior convenience, the 5-day regimen remains a validated option.

Key Timing Consideration

  • Start treatment within 6 hours of symptom onset for optimal efficacy with the 1-day regimen 1
  • Treatment started during prodrome or within 1 day of lesion onset provides maximum benefit 2

Suppressive Therapy for Frequent Recurrences

For patients with frequent recurrences (≥6 episodes per year), famciclovir 250 mg twice daily is the recommended suppressive dose 2, 1. This regimen:

  • Reduces recurrence frequency by ≥75% 2
  • Has documented safety and efficacy for up to 1 year 2
  • Does not eliminate asymptomatic viral shedding 2

Important limitation: At the time of the 1998 CDC guidelines, insufficient experience prevented recommending famciclovir suppression beyond 1 year 2. After 1 year of continuous therapy, reassess the patient's recurrence rate and psychological adjustment to determine if continuation is warranted 2.

Special Populations

HIV-Infected Patients

500 mg twice daily for 7 days for recurrent orolabial or genital herpes 1. Treatment can be initiated up to 48 hours after symptom onset in this population 1.

Renal Impairment

Dose adjustments are critical to prevent acute renal failure 1:

For 1-day episodic treatment (recurrent genital herpes):

  • CrCl ≥60: 1000 mg every 12 hours for 1 day
  • CrCl 40-59: 500 mg every 12 hours for 1 day
  • CrCl 20-39: 500 mg single dose
  • CrCl <20: 250 mg single dose
  • Hemodialysis: 250 mg single dose following dialysis 1

For suppressive therapy:

  • CrCl ≥40: 250 mg every 12 hours
  • CrCl 20-39: 125 mg every 12 hours
  • CrCl <20: 125 mg every 24 hours
  • Hemodialysis: 125 mg following each dialysis 1

Clinical Pearls

  • Provide patients with medication in advance so they can self-initiate treatment at the earliest sign of recurrence 2
  • The 1-day regimen (1000 mg BID × 1 day) offers comparable efficacy to longer courses with superior convenience 3, 4
  • Resistance to penciclovir (famciclovir's active metabolite) remains rare in immunocompetent patients 3, 5
  • Single-day treatment does not shorten time to next recurrence compared to 3-day valacyclovir regimens 3

Common Pitfall

Do not use famciclovir for first-episode genital herpes - efficacy and safety have not been established in this setting 1. First episodes require longer treatment courses with acyclovir or valacyclovir.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.